“For the clinician, there’s a value triad of efficacy, toxicity, and cost,” says Bruce Feinberg, DO, a vice president and chief medical officer of Cardinal Health Specialty Solutions during the fourth part and conclusion of the one-on-one interview series on PD-1 agents. He echoes the thoughts of many payers: Cost becomes the paramount differentiator in the case of multiple oncology drugs that are similar in terms of improving survival, quality of life, and safety.

Dr Feinberg remarks that PBMs make decisions based primarily on cost even if a new drug is administered once daily versus an older regimen that requires a combination of seven pills a day to treat the same condition (eg, hepatitis C). He pointed out that this consideration may apply to the multiple PD-1 agents as well as the biosimilars as they are approved by the Food and Drug Administration (FDA). However, the costs of new specialty medications have become such an issue that some stakeholders are starting to “blur the lines of that value triad, which was fairly consistently upheld for the last two decades.”

If multiple agents are available for a given target, Michael Kolodziej, MD, a national medical director of oncology strategy for Aetna, believes that it would be almost impossible that they would not be covered should the FDA approve it and “the NCCN gives it its blessing.” As a result, he doubts that current discussions about more aggressively managing oncology formularies through will bear fruit.

Dr Kolodziej believes the clinical pathways are the best way today to apply that value triad of efficacy, toxicity, and cost of care. Therefore, it becomes critical to focus on building the pathway (and not deciding whether to cover an individual oncologic medication); pathways are truly an alternative for approaching the formulary management question, comments Dr Kolodziej. 

Critical Influences for PD-1 Treatments

As part of the one-on-one The Clinical and Reimbursement Landscape of Immuno-Oncology interview series on PD-1 inhibitors, Michael Kolodziej, MD, and Bruce Feinberg, DO, considered the implications for coverage and treatment pathways when 2 different molecules have the same target and indications. This discussion also addressed efficacy, toxicity, and cost of multiple agents.
Published Online: June 02, 2015
View More From This Discussion
Episode 1 Determining the Place of PD-1s in Therapy
Episode 2 Cost Issues Related to PD-1 Treatment
Episode 3 Precision Medicine, the Oncology Care Model, and PD-1s
Episode 4 Critical Influences for PD-1 Treatments
Episode 5 Rationale for Immuno-Oncology
Episode 6 Considerations Related to the Coverage of Immuno-Oncology Therapies
Episode 7 NRAS Mutations in Melanoma
Episode 8 Sequencing of Immunotherapy in Melanoma
Episode 9 Determining Appropriate Duration of Treatment
Episode 10 Considerations When Switching Therapy
Episode 11 Anti-PD-1 Treatment Selection
Episode 12 Anti-PD-1 Agents as Frontline Therapy
Episode 13 The Rationale for Initiating Therapy with an Immuno-Oncology Drug
Episode 14 Targeted Therapies and the Sequencing of Immuno-Oncology Drugs
Episode 15 Integrating Immunotherapy in Lung Cancer
Episode 16 Measuring Response With Immuno-Oncology Agents in NSCLC
Episode 17 The Cost of Care in Immuno-Oncology
Episode 18 Appropriate, Value-Based Care in Immuno-Oncology
$RAmodule$